HCW Biologics Inc.
HCWB evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $4.1M
- Lead Asset:
- hcw9302 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for HCWB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HCWB
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, with a lead candidate targeting a Phase 1 trial in the second half of 2027.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$4.1M
Cash Runway
—
Lead Asset
hcw9302 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 18 clinical trials for HCW Biologics Inc..
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, with a lead candidate targeting a Phase 1 trial in the second half of 2027.
- Cash & equivalents of $0.7M as of 2026-06-30 [sec].
- Net loss of -$5.2M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $7.4M as of 2026-06-30 [sec].
- Lead product candidate HCW11-018b is a fusion molecule combining a PD-1 inhibitor with an IL-15 receptor agonist, showing superior immune-cell activation compared to pembrolizumab in preclinical studies [sec · filed 2026-10-02].
- Company plans to initiate a Phase 1 clinical study for HCW11-018b in a senescence-associated dysplasia indication in the second half of 2027 [sec · filed 2026-10-02].
What works
- Founder and CEO Dr. Hing C. Wong previously discovered and developed Anktiva® (IL-15 receptor agonist), which was sold for $1.0 billion and received FDA approval in April 2024 [sec_mda · as of 2026-08-14].
- Lead candidate HCW11-018b demonstrates superior immune-cell activation, expansion, and cytotoxicity against cancer cells compared to pembrolizumab in in-vitro and in-vivo studies [sec · filed 2026-10-02].
- Company has a commercial-ready reagent HCW9206 for CAR-therapy production, with plans to commercialize through a corporate partnership in the second half of 2026 [sec · filed 2026-08-20].
What to weigh
- Very limited cash position of $0.7M as of 2026-06-30, which may constrain operations and clinical development [sec].
- Net loss of $5.2M for the period ended 2026-06-30 indicates ongoing cash burn without near-term revenue from product sales [sec].
- All product candidates are in preclinical or early clinical stages, with no approved products or near-term revenue expected [sec · filed 2026-10-02].
- Heavy reliance on third-party suppliers and manufacturers for clinical trials and manufacturing, introducing operational risk [sec · filed 2026-10-02].
From the filings
Quoted directly from source documents.
Lead candidate shows superior immune-cell activation compared to pembrolizumab
“it exhibits superior immune-cell activation, expansion, and cytotoxicity against cancer cells and tumors when compared to pembrolizumab in in-vitro and in-vivo studies”
SEC filings · October 2, 2026
Founder previously developed Anktiva® which was approved by FDA
“experienced team led by Dr. Hing C. Wong, our Founder and CEO, who discovered and developed the immunotherapeutic Anktiva® (also known as ALT-803, an IL-15 receptor agonist) through pivotal trials. This blockbuster immunotherapeutic treatment for cancer was sold to ImmunityBio, Inc. in 2017 in a $1.0 billion acquisition. In April 2024, Anktiva® was approved by the U.S. Food and Drug Administration”
SEC MD&A · August 14, 2026
Phase 1 trial planned for second half of 2027
“The Company plans to initiate a Phase 1 clinical study in a senescence-associated dysplasia indication in the second half of 2027”
SEC filings · October 2, 2026
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash of $0.7M as of 2026-06-30 may be insufficient to fund operations and clinical trials without additional financing [sec].
- Clinical stage risk
- Dependence on third parties — Reliance on third-party suppliers and manufacturers for clinical trials and manufacturing introduces operational risk [sec · filed 2026-10-02].
What to watch
- Initiation of Phase 1 clinical study for HCW11-018b in senescence-associated dysplasia in H2 2027 [sec · filed 2026-10-02].
- Commercialization of HCW9206 through corporate partnership in H2 2026 [sec · filed 2026-08-20].
- IND filing for HCW11-018b in cancer in H1 2027 [sec_mda · as of 2026-08-14].
- IND filing for HCW11-040 in bronchopulmonary dysplasia in H2 2027 [sec_mda · as of 2026-08-14].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run HCW Biologics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HCW Biologics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.60 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
6 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 9.3%
- Days to cover
- 0.3
- Shares short
- 570,862
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HCWB short interestGovernance
Frequently asked questions
What is the AI investment thesis for HCW Biologics Inc.?
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, with a lead candidate targeting a Phase 1 trial in the second half of 2027.
What is HCW Biologics Inc.'s lead drug candidate?
HCW Biologics Inc.'s most advanced tracked candidate is hcw9302 (Phase 1) for Alopecia Areata(AA).
Who is the CEO of HCW Biologics Inc.?
Dr. Hing C. Wong Ph.D. is the chief executive officer of HCW Biologics Inc. (HCWB).
Where is HCW Biologics Inc. headquartered?
HCW Biologics Inc. (HCWB) is headquartered in Miramar, FL, United States.
What therapeutic areas does HCW Biologics Inc. focus on?
HCW Biologics Inc. develops therapies across Oncology, Immunology, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Musculoskeletal, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.